Ignite Creation Date:
2024-05-05 @ 10:41 PM
Last Modification Date:
2024-10-26 @ 10:22 AM
Study NCT ID:
NCT01166126
Status:
TERMINATED
Last Update Posted:
2014-05-15
First Post:
2010-07-12
Brief Title:
TemsirolimusAZD 6244 for Treatment-naive With BRAF Mutant Unresectable Stage IV
Sponsor:
National Cancer Institute NCI
Organization:
National Cancer Institute NCI
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Stage IV Melanoma |
| Mucosal Melanoma |
| Recurrent Melanoma |
Keywords: